**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 59741

**Manuscript Type:** MINIREVIEWS

**Platelet-rich plasma *vs* bone marrow aspirate concentrate: An overview of mechanisms of action and orthobiologic synergistic effects**

Lana JFSD *et al*. PRP *vs* BMAC

José Fábio Santos Duarte Lana, Lucas Furtado da Fonseca, Rafael da Rocha Macedo, Tomas Mosaner, William Murrell, Ashok Kumar, Joseph Purita, Marco Antonio Percope de Andrade

**José Fábio Santos Duarte Lana, Tomas Mosaner,** Department of Orthopedics, The Bone and Cartilage Institute, Indaiatuba 13334-170, SP, Brazil

**Lucas Furtado da Fonseca,** Department of Orthopedics, The Federal University of São Paulo, São Paulo 04023-062, SP, Brazil

**Rafael da Rocha Macedo,** Department of Orthopedics, Rede D’Or Unit IFOR Hospital, São Bernardo do Campo 09715-021, SP, Brazil

**William Murrell,** Department of Orthopaedics, Healthpoint UAE, Abu Dhabi 00000, United Arab Emirates

**Ashok Kumar,** Department of Orthopaedics, My Doc Specialist Medical Centre, Dubai 00000, United Arab Emirates

**Joseph Purita,** Department of Orthopedics, Institute of Regenerative Medicine, Boca Raton, FL 33432, United States

**Marco Antonio Percope** **de Andrade,** Department of Orthopaedic, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil

**Author contributions:** Purita J wrote the manuscript; de Andrade MAP proposed the research subtopics; Kumar A was responsible for navigating the literature and sharing the relevant studies that were included in this review; Murrell W and da Fonseca LF shared significant knowledge regarding the use of orthobiologics in regenerative medicine; Mosaner T formatted the citations and compiled the references; Macedo RR revised and formatted the body of the manuscript and verified spelling, punctuation and grammatical errors; Lana JFSD was responsible for reviewing and approving all the modifications made to the manuscript from draft to final version.

**Corresponding author: José Fábio Santos Duarte Lana, MD, Chief Doctor, Surgeon,** Department of Orthopedics, The Bone and Cartilage Institute, 1386 Presidente Kennedy Avenue, Indaiatuba 13334-170, SP, Brazil. josefabiolana@gmail.com

**Received:** September 26, 2020

**Revised:** December 15, 2020

**Accepted:** January 15, 2021

**Published online:**

**Abstract**

The use of orthobiologics as a novel therapy for the treatment of numerous musculoskeletal disorders has increased considerably over the past decade. Currently, there are multiple alternatives available as suitable treatments; however, the use of autologous blood-derived products such as platelet-rich plasma (PRP), bone marrow aspirate (BMA) and BMA concentrate (BMAC), specifically, is expanding. Although many investigations attempted to demonstrate the effectiveness of these therapies, even with positive results, the literature lacks standardized protocols and overall accuracy in study designs, which leads to variance and difficulty in reproducibility of protocols. The efficacy of PRP for the treatment of cartilage, bone and muscle tissues is well known. Although BMAC has generated optimistic results for the same purposes, its applicability in clinical trials is still relatively recent when compared to PRP. Both products demonstrate the potential to set forth reparative processes, each in their own distinct mechanism. The combination of these biological products has been previously proposed, yet little is known about their synergism. Evidence indicates that growth factor, cytokine, and chemokine profiles seen in both PRP and BMAC vary but are likely to work synergistically to enhance musculoskeletal healing. BMAC products seem to work well without PRP; however, the addition of PRP to BMAC has been shown to act as a rich and natural source of culture medium for stem cells located either peripherally or in the bone marrow itself. Nevertheless, additional variables associated with the use of BMAC and PRP in orthopedics must be further evaluated in order to consolidate the efficacy of this therapeutic strategy.

**Key Words:** Orthobiologics; Platelet-rich plasma; Bone-marrow aspirate; Regenerative medicine; Musculoskeletal diseases; Stem cells

Lana JFSD, da Fonseca LF, Macedo RDR, Mosaner T, Murrell W, Kumar A, Purita J, de Andrade MAP. Platelet-rich plasma *vs* bone marrow aspirate concentrate: An overview of mechanisms of action and orthobiologic synergistic effects. *World J Stem Cells* 2021; In press

**Core Tip:** Degenerative musculoskeletal disorders are one of the top causes of pain and disability in the adult population. The use of certain analgesics delivers short term results but do not address the etiological source of pain and disability. The demand for musculoskeletal tissue regeneration has led to an alternative approach referred to as orthobiologics, which is based on cellular and molecular components capable of promoting tissue repair. Platelet-rich plasma and bone marrow aspirate concentrate are popular orthobiologic products that may work synergistically in order to enhance the treatment of musculoskeletal conditions.

**INTRODUCTION**

Musculoskeletal diseases have a high prevalence in adults. One out of every two adults may find themselves suffering from any sort of musculoskeletal disorders, and incidentally, knee pathologies are presented as one of the most common diseases in the United States. Additionally, in 2017, this pathology was the highest contributor to global disability[1], leading to the greatest proportion of lost productivity in the workplace and higher costs of treatment, reaching up to US$ 874 billion[2]. A major gap for the treatment of these musculoskeletal conditions exists between conservative therapy and surgery. Orthobiologics are substances that are naturally found in the human body and are used by orthopedic surgeons to improve the healing of cartilage, injured muscles, tendons, ligaments, and fractures. They provide a less invasive alternative and potential disease-modifying properties that might be beneficial for injured patients[3].

In regenerative medicine, the use of orthobiologics as a novel therapy for the treatment of several orthopedic conditions has increased over the past decade. Current therapies include platelet-rich plasma (PRP), bone marrow aspirate (BMA), BMA concentrate (BMAC), stromal vascular fraction of adipose tissue, and cell-derived therapies[3]. Several studies attempted to demonstrate the effectiveness of those therapies. However, even with positive results there is still a need for standardization protocols and greater accuracy in the study design[4-6]. A growing number of preclinical and clinical trials have demonstrated the efficacy of PRP to treat cartilage, bone, and muscle lesions[7]. The use of BMAC in clinical trials is relatively new when compared to PRP. However, good to excellent results have been demonstrated, especially in the treatment of chondral lesions[8,9].

Either PRP or BMAC has the potential to support tissue repair but with different intensity and in distinct pathways. The use of these biological products together has been described, yet little is known about their synergism. This study aims to explore the literature in regard to the combined use of PRP and BMAC in musculoskeletal injuries and review their applicability in the clinical setting.

**PRP**

PRP is a bioproduct that has a higher number of platelets, usually three to five times above baseline in a small fraction of plasma or greater than 1.0 × 106 platelets/μL, and it is obtained through centrifugation[10,11]. Concentrations over 1.5 million platelets/μL might cause inhibition on stem cell proliferation in an *in vitro* setting. The biological mechanism driving the clinical use of PRP involves the action of growth factors (GFs) which are released from alpha granules of activated platelets. Examples include vascular endothelial GF (VEGF), epidermal GF (EGF), platelet-derived GF (PDGF), transforming GF-beta1 (TGF-β1), basic fibroblast GF (b-FGF), hepatocyte GF, and other bioactive compounds released from dense granules in a lesser amount[12,13]. Upon activation, platelets will seek out the receptors on the cell membrane surface of a stem cell. These cells have receptors that bind GFs and, in turn, elicit local downstream effects. In general, most GFs play important roles associated with migration, differentiation, and proliferation of cells as well as extracellular matrix biosynthesis, driving tissue repair and regeneration[14]. PRP also contains a number of different cell types including neutrophils (which represent 40%-75% of the circulating leukocytes), monocyte/macrophages (representing 2%-10% of the circulating leukocytes), fibroblasts (which produce collagen, reticular fibers, glycosaminoglycans and glycoproteins), endothelial cells, and possibly a very small amount of primitive mesenchymal type stem cells[15].

Recently, the participation of other blood components in the tissue healing process (in addition to the involvement of GFs) has been discussed. White blood cells, for example, upon combination with platelets can stimulate the generation of anti-inflammatory cytokines even though they are naturally involved in important roles in microbicidal activity with the production of inflammatory cytokines[16,17]. Another component that should be taken into account is the fibrin biopolymer, which is a final product of platelet cascade activation and acts as a temporary three-dimensional extracellular matrix, providing a suitable vehicle for the delivery of bioactive molecules, such as GFs[18]. As the fibrin bio-scaffold is degraded, the platelet masses are gradually decomposed, and the steady release of GFs is maintained for 7 to 10 d in the local microenvironment[19]. Basically, when platelets are activated, there is an initial burst of GFs that is later stabilized and kept under a sustained release.

Indeed, much has been debated about the presence or absence of leukocytes[20], type of activation, and the use of the fibrin polymer, which generates several blood-derived sub-products: plasma rich in GFs, pure or leukocyte-poor PRP (Lp-PRP), leukocyte-rich PRP (Lr-PRP), pure platelet-rich fibrin, leukocyte- and platelet-rich fibrin[21,22]. Lr-PRP and leukocyte-poor PRP may have similar safety profiles in regard to adverse reaction[23], and Lr-PRP does not modify systemic and local levels of proinflammatory cytokines in osteoarthritic knees, for example[24]. The rationale for the use of Lr-PRP seems to be the crosstalk between platelets and neutrophils. After initial release of inflammatory molecules (arachidonic acid, leukotrienes, and prostaglandins), lipoxin A4 is released from activated platelets and serves as a stop signal from primed neutrophils to prevent neutrophil activation[17]. In regard to the influence of type of PRP on mesenchymal stem cell (MSC) cultures, Lr-PRP is able to induce significantly higher proliferation of bone marrow (BM)-MSCs when compared with pure PRP or platelet-poor plasma samples, with faster release and better biological activity of GFs[25].

Over the past decade, several studies evaluating the use of PRP as a therapeutic product for musculoskeletal injuries have been published, as Table 1 indicates. Numerous authors evaluated the effect of PRP after muscle injuries in athletes and found a reduction in pain, an improvement in the physical recovery and faster regeneration when compared with conventional conservative treatments[26]. Some randomized controlled trials reported positive outcomes in the reduction of pain scores on total knee arthroplasty[27], plantar fasciitis[28], and arthroscopic rotator cuff repair[29], for example. However, some systematic reviews exhibit no functional improvements following anterior cruciate ligament (ACL) reconstruction[30] and knee function[31,32]. This contradictory functionality of PRP may occur due to the lack of standardization of protocols for PRP preparation and the variety of methods for evaluating effectiveness as well as the high availability of scores that may vary among them[33]. In fact, a recent analysis reporting PRP processing for musculoskeletal conditions (105 studies) showed that only 11.5% of studies reported on all necessary variables of PRP processing required to reproduce the protocol[34].

Despite promising results, most of the literature has reported PRP to be beneficial only for a short period. Besides, the association of PRP and additional therapeutic components such as hyaluronic acid or cell therapy may potentially provide better functional outcomes in the clinical setting[35,36]. Research on these combinatory treatments possibly provides insights into the involved processes in physiological healing and pathological failure.

**BMAC**

MSCs present in BMAC products are multipotent stem cells and have been used in the orthopedic field due to their strong self-renewal capacity along with the potential to differentiate into all musculoskeletal lineages. MSCs are a secretory organ of cytokines, chemokines, GFs, and anti-inflammatory molecules that promote the recovery of the injured tissue[8]. According to The International Society for Cellular Therapy Position Statement, there are four minimum criteria for MSC identification: (1) MSCs must be plastic-adherent when cultured under standard conditions; (2) MSCs must demonstrate the capacity for osteogenic, adipogenic, and chondrogenic differentiation; (3) MSCs must express CD73, CD90, and CD105; and (4) MSCs must lack expression of hematopoietic lineage markers (*e.g.*, CD34, CD45, CD14, HLA-DR)[37]. The number of progenitor cells in BMAC correlates with positive outcomes; however, obtaining a high number of cells depends on several factors like age of the patient, the method used to prepare BMAC as well as association with other biological products, such as PRP[14]. Also, BM aspiration seems to be technique-driven depending on the skills of the physician.

Recently, the capacity of MSCs towards differentiation has been debated, and several studies highlight their potential role in the regenerative microenvironment. In *in vivo* scenarios,they act as a sort of medicinal drugstore for immunomodulation and anabolic stimulation of the host microenvironment[38]. MSCs make up a small fraction of BMA, in a proportion of approximately 1 cell for every 10000 cells on average depending on the individual’s age. On the other hand, they are easy to isolate because MSCs can be obtained from BM, adipose tissue, dental pulp, umbilical cord blood, fetal liver, and amniotic fluid[39,40]. They also possess a strategic role in the regenerative process mainly *via* the capacity of self-renewal, proliferation, differentiation, and homing effects in order to recruit more cells to the injury site[41]. MSCs can be found in every vascularized tissue in the body because these cells are perivascular in nature, which is why they are often referred to as pericytes by many authors[42]. In fact, some pericytes are attracted to the injury site and become activated MSCs. These MSCs present in BMAC have immunomodulatory, anti-inflammatory, and antiapoptotic mechanisms that will vary according to the environment and as a response will secrete large quantities of different bioactive molecules[43,44].

After birth, BM becomes the only responsible tissue for the production of hematopoietic and stromal cells. Briefly, hematopoietic stem cells (HSCs) are responsible for giving rise to other blood cell lines, such as red blood cells, leukocytes, platelets, and granulocytes[45]. On the other hand, MSCs can differentiate into fibroblasts, osteoblasts, osteocytes, adipocytes, and chondrocytes[46,47]. It has been suggested that HSCs are the drivers of tissue regeneration by upregulating cytokine release and stimulating additional stem cells from intact bone to travel to the site of injury. Also, HSCs have been shown to directly form bone by differentiating into MSCs and then osteoblasts[45]. In order words, the presence of HSCs augments the limited number of available stromal cells, orchestrating cellular cooperation to achieve tissue regeneration. Another advantage for the use of BMAC is that the technique is considered minimal cellular manipulation and thus having FDA approval for the delivery of stem cells[48]. BMAC contains a mixed cell population, which is believed to enhance its performance as MSCs are in contact with their physiological cell niche[49]. It is considered a low complication procedure concerning hemorrhage, joint pain, and swelling[50].

Much like PRP, BMAC has some discrepancies in its obtainment and processing protocol. Therefore, in a recent review it was recommended for BM aspiration procedures to be made from the posterior iliac crest due to the highest concentration of MSCs because it is the safest area due to the remoteness to neurovascular structures[51,52]. Syringe sizes (preferably 10 ccs syringe) and aspiration volumes (3-4 ccs per syringe) should be considered because higher sizes and volumes per puncture might induce diluted samples and fewer MSCs and other regenerative cells[53]. Another concern is the use of commercial kits. Most of these automatic systems are based on gradient separation by centrifugation that allows achievement of 2-8 × more total nucleated cells in comparison to unprocessed BM. Gaul *et al*[54] reported an extensive comparison of technical features classified into two groups: (1) fully automated and closed-loop systems; and (2) manual extraction of the buffy coat. Despite the quality criteria between those products (based on hematocrit, the platelet count, and the concentration of MSC), the study concluded that they could not recommend a single system because the reported data could not be compared between devices.

**PRP and BMAC Synergism**

There are appreciable studies in the body of literature that investigate the synergistic effects between PRP and BMAC (Table 1). A recent study evaluating stem cell culture in PRP medium revealed a 5-fold or greater increase in the number of HSCs produced when compared to culturing them in whole blood or platelet poor plasma[55], which can be translated into clinical practice. PRP injections have also been shown to stimulate MSC proliferation and ACL cellular growth enhancement *in vivo*[56]. Interestingly, it has been previously demonstrated in a rabbit model that PRP in combination with BMAC does improve ACL integrity whereas PRP alone yielded mixed results[57].

An extensive review of the *in vitro* perspective on PRP and MSC partnership revealed that PRP stimulates MSC proliferation in a nontumorigenic manner, preserves MSC multipotency, and does not interfere with multilineage differentiation[58]. PRP may also delay the appearance of senescent features. In all 57 articles included in the review, PRP increased the number of cells and velocity of population doublings[58]. PRP also protected MSCs from chromosomal instability. Additionally, MSCs cultured with PRP were able to preserve their immune-privileged potential by altering cytokine secretion of immune cells (T lymphocytes, B cells, and natural killer cells) to an anti-inflammatory profile and inhibited amplification of adaptive immune response[58].

These findings encourage the clinical application of MSCs along with PRP in a delicate balance between multiple pro- and antiproliferative molecules because increasing PRP concentrations in culture does not necessarily increase proliferation of MSCs[59]. MSCs are also difficult to obtain in large quantities as their concentration in peripheral blood and BM is low (0.001%-0.010% of mononuclear cells in BMA). In spite of this disadvantage, MSCs have consistently shown the potential to increase their proliferation when cultured with PRP[60]. For cartilage healing, subchondral progenitor MSCs were stimulated to migrate in the presence of PRP and underwent chondrogenic differentiation with an increase in type II collagen matrix deposition[61].

Based on *in vivo* studies, it seems logical that PRP increases vascular ingrowth and mitogenic effects on bone-forming cells[62]. At the same time, BMAC provides progenitor cells as a natural source of autologous bone tissue embedded in cytokines, GFs and also platelets. Nevertheless, well-controlled comparative studies regarding the bone regenerative capability of these two concentrates isolated from peripheral blood and BM remain scarce, and results are controversial. A clinical study showed that PRP had better potential for alveolar bone augmentation when compared with BM-MSCs[63]. Conversely, an experimental study claimed that BM-MSCs displayed superior effects on bone regeneration in comparison to PRP[64]. The differences revealed by the literature so far prompt a better understanding of both orthobiologic products and their complementary use.

A recent level I study with the use of autologous BMAC combined with PRP injection at the site of osteotomy in the same procedure assisted in the improvement of bone regeneration with a better cortical consolidation in distraction osteogenesis of the tibia in comparison to the control group[65]. In another prospective study, BMAC and PRP were applied percutaneously in 23 patients with grade 1, 2, or 3 ACL tears with less than 1 cm retraction under fluoroscopic guidance. The majority (77%) of patients showed significant improvements (*P* < 0.01) in objective measurements of ACL integrity at an average of 8.8 mo. Mean scores were found to be significantly different (*P* < 0.05) for the Numerical Pain Scale at 6, 18, and 24 mo, and Lower Extremity Functional Scale and International Knee Documentation Committee at all-time points (*i.e.*, 1, 3, 6, 12, 18, 24, and 36 mo) relative to baseline[66].

In a clinical study, ten patients were treated with the combined use of BMAC and PRP for full-thickness cartilage lesions in the knees. All patients improved in clinical and pain scores at 1 and 2 years postoperatively. Magnetic resonance imaging MOCART scores also improved significantly from baseline[67]. The authors emphasized that the combination of BMAC with PRP is an attractive one-step procedure for cartilage repair although no quantification of BMAC and PRP cells were made in the study. The combination also demonstrated a benefit for the treatment of gluteus minimus tendon tear and hip capsular defect in high-performance athletes[68]. This may be attributed to the accelerated cell replication and collagen production that PRP promotes as demonstrated on MSCs contained in BMAC[69].

Treatment of osteonecrosis of the femoral head (Ficat stage I or II) with BMAC plus PRP has also been shown to be a good augmentation strategy during minimally invasive decompression of the femoral head in 77 hips with significant pain relief in 86% of patients and only progression to further stages of osteonecrosis in 21%[70]. In respect to discogenic low back pain, a recent comprehensive review found that percutaneous, fluoroscopy-guided, intradiscal PRP and BMAC application appears to be safe and potentially positive but is limited due to low-quality studies, natural history of discogenic pain, and variable reporting characteristics[55].

In the first randomized controlled trial of BMAC and PRP injections for partial and full-thickness nonretracted supraspinatus tears in a nonsurgical setting, the combined biological therapy showed better outcomes in comparison to exercise therapy[71]. Patients reported a mean 89% improvement at 24 mo with sustained functional gains and pain reduction. Magnetic resonance imaging blinded reviews showed a size decrease of most tears post-treatment. Similar results were shared by another study for partial tear of the rotator cuff with the BMAC-PRP treatment[72]. It was previously demonstrated that BMAC-PRP enhanced the proliferation and migration of tendon derived stem cells and prevents the aberrant chondrogenic and osteogenic differentiation of tendon derived stem cells in rotator cuff tendon tears[72].

From a cellular composition and cytokine concentrations analysis, BMAC and PRP present overlapping results. In a well-analyzed study, BMAC showed more PDGF, TGF-b, and VEGF in comparison to PRP preparation with no statistically significant difference. Interleukin (IL)-1ra, a potent anti-inflammatory cytokine, was significantly increased in BMAC compared to PRP[73]. In another similar study, it was verified that BMAC and PRP had no significant differences in the level of three GFs (PDGF, TGF-b, and VEGF), but PRP still appeared to be more favorable overall. BMAC presented significantly higher basic fibroblast GF levels than PRP[74]. This GF is known to induce cell proliferation and chondrogenic differentiation in human BM-MSCs. A recent study aimed to analyze BMA harvested from the posterior iliac crest, BMAC, Lr-PRP, and leukocyte-poor PRP for GF and cytokine concentrations. BMAC seemed to be a clinically relevant source of anti-inflammatory biologic therapeutic due to its significantly higher concentration of IL-1Ra. Lr-PRP may be optimal in cases where increased vascularity and healing are desired given its greater overall concentrations of PDGF, TGF-b, epidermal GF, VEGF, and soluble CD-40 ligand[75].

**Author’s Preference**

To address the concerns of possible inferior regeneration capacity of orthobiologics as a single treatment, studies have recently been practicing the combined treatment of PRP and BMAC for specific types of musculoskeletal injuries. This is encouraged by a premise of having the benefits of progenitor cells, including hematopoietic cells, and a great amount of GFs (Figure 1). Stromal-derived factor-1a is a major homing chemokine stored in the alpha-granules[76] for stem cells (*via* CXCR-4) to act in the site of injury. Additionally, the macrophage, as part of the mononuclear cells found in the BM, has a great plasticity potential and can switch phenotypes from the M1 to the M2 subtype in order to attenuate chronic inflammation (Figure 1).

The combination of PRP with BMAC appears to mimic the natural cascade that occurs in fractured bone healing. Initially, there is a major influx of neutrophils into the fracture hematoma; these cells are then replaced by macrophages *via* the secretion of several macrophage chemo-attractants, such as monocyte chemotactic protein-1[77]. Subsequently, there is a shift to the anti-inflammatory M2 macrophage and selectively recruited lymphocytes. M2 macrophages secrete high levels of anti-inflammatory cytokines and fibrogenic and angiogenic factors that serve to resolve inflammation and stimulate tissue regeneration. Posteriorly, granulation tissue is formed along with fibrinolysis of the fracture hematoma. Fibrin degradation attracts and facilitates MSC invasion and further proliferation and differentiation within the injured area.

For PRP preparation, two centrifugations (320 × *g* for 5 min and then 700 × *g* for 17 min) with collection of the buffy coat (Lr-PRP) followed by cold preconditioning at 4 °C and light (LED) bath for 20 min is recommended as described in the literature[78-80]. For BMAC preparation, double centrifugation is also set (40 × *g* for 20 min and then 800 × *g* for 10 min) along with the same storage and activation parameters described in PRP preparation.

**CONCLUSION**

Although essential developments have been made in the field of orthobiologics, this combined therapy deserves further substantial improvements. From the basic science to clinical application, evidence shows that GF, cytokine, and chemokine profiles seen in PRP and BMAC are different and likely work synergistically to enhance musculoskeletal healing. Nevertheless, there are still numerous potential variables associated with the use of BMAC and PRP in orthopedics that must be further evaluated. These variables include the optimal number of cells required for superior healing, steady rate of GF release, ideal time interval for the introduction of cells and GFs, dose-response curves, and the method of processing (*i.e.*, centrifugation and activation). It is then important to define a minimal standard for each of these treatments and set a clear nomenclature system for appropriate communication. Although BMAC seems to work well without PRP, evidence supporting PRP as an orthobiologic is massive. The addition of PRP to BMAC provides a natural source of culture medium for MSCs located either peripherally or in the BM. Future randomized clinical trials with well-designed protocols and well-defined controls and parameters are needed in order to consolidate the efficacy of this combined therapy.

**REFERENCES**

1 **GBD 2017 Disease and Injury Incidence and Prevalence Collaborators**. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1789-1858 [PMID: 30496104 DOI: 10.1016/S0140-6736(18)32279-7]

2 **Kraeutler MJ**, Chahla J, LaPrade RF, Pascual-Garrido C. Biologic Options for Articular Cartilage Wear (Platelet-Rich Plasma, Stem Cells, Bone Marrow Aspirate Concentrate). *Clin Sports Med* 2017; **36**: 457-468 [PMID: 28577706 DOI: 10.1016/j.csm.2017.02.004]

3 **Moatshe G**, Morris ER, Cinque ME, Pascual-Garrido C, Chahla J, Engebretsen L, Laprade RF. Biological treatment of the knee with platelet-rich plasma or bone marrow aspirate concentrates. *Acta Orthop* 2017; **88**: 670-674 [PMID: 28831830 DOI: 10.1080/17453674.2017.1368899]

4 **Bennell KL**, Hunter DJ, Paterson KL. Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis. *Curr Rheumatol Rep* 2017; **19**: 24 [PMID: 28386761 DOI: 10.1007/s11926-017-0652-x]

5 **Grassi A**, Napoli F, Romandini I, Samuelsson K, Zaffagnini S, Candrian C, Filardo G. Is Platelet-Rich Plasma (PRP) Effective in the Treatment of Acute Muscle Injuries? A Systematic Review and Meta-Analysis. *Sports Med* 2018; **48**: 971-989 [PMID: 29363053 DOI: 10.1007/s40279-018-0860-1]

6 **Mautner K**, Malanga GA, Smith J, Shiple B, Ibrahim V, Sampson S, Bowen JE. A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature. *PM R* 2015; **7**: S53-S59 [PMID: 25864661 DOI: 10.1016/j.pmrj.2015.02.005]

7 **Spaková T**, Rosocha J, Lacko M, Harvanová D, Gharaibeh A. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. *Am J Phys Med Rehabil* 2012; **91**: 411-417 [PMID: 22513879 DOI: 10.1097/PHM.0b013e3182aab72]

8 **Yamaguchi FSM**, Shams S, Silva EA, Stilhano RS. PRP and BMAC for Musculoskeletal Conditions *via* Biomaterial Carriers. *Int J Mol Sci* 2019; **20** [PMID: 31717698 DOI: 10.3390/ijms20215328]

9 **Krych AJ**, Nawabi DH, Farshad-Amacker NA, Jones KJ, Maak TG, Potter HG, Williams RJ 3rd. Bone Marrow Concentrate Improves Early Cartilage Phase Maturation of a Scaffold Plug in the Knee: A Comparative Magnetic Resonance Imaging Analysis to Platelet-Rich Plasma and Control. *Am J Sports Med* 2016; **44**: 91-98 [PMID: 26574602 DOI: 10.1177/0363546515609597]

10 **Marx RE**. Platelet-rich plasma (PRP): what is PRP and what is not PRP? *Implant Dent* 2001; **10**: 225-228 [PMID: 11813662 DOI: 10.1097/00008505-200110000-00002]

11 **Marx RE**, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1998; **85**: 638-646 [PMID: 9638695 DOI: 10.1016/s1079-2104(98)90029-4]

12 **El-Sharkawy H**, Kantarci A, Deady J, Hasturk H, Liu H, Alshahat M, Van Dyke TE. Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties. *J Periodontol* 2007; **78**: 661-669 [PMID: 17397313 DOI: 10.1902/jop.2007.060302]

13 **Sundman EA**, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. *Am J Sports Med* 2011; **39**: 2135-2140 [PMID: 21846925 DOI: 10.1177/0363546511417792]

14 **LaPrade RF**, Geeslin AG, Murray IR, Musahl V, Zlotnicki JP, Petrigliano F, Mann BJ. Biologic Treatments for Sports Injuries II Think Tank-Current Concepts, Future Research, and Barriers to Advancement, Part 1: Biologics Overview, Ligament Injury, Tendinopathy. *Am J Sports Med* 2016; **44**: 3270-3283 [PMID: 27159318 DOI: 10.1177/0363546516634674]

15 **Andia I**, Abate M. Platelet-rich plasma: combinational treatment modalities for musculoskeletal conditions. *Front Med* 2018; **12**: 139-152 [PMID: 29058255 DOI: 10.1007/s11684-017-0551-6]

16 **Lana JF**, Macedo A, Ingrao ILG, Huber SC, Santos GS, Santana MHA. Leukocyte-rich PRP for knee osteoarthritis: Current concepts. *J Clin Orthop Trauma* 2019; **10**: S179-S182 [PMID: 31700210 DOI: 10.1016/j.jcot.2019.01.011]

17 **Parrish WR**, Roides B. Physiology of Blood Components in Wound Healing: an Appreciation of Cellular Co-Operativity in Platelet Rich Plasma Action. *J Exerc Sport Orthop* 2017; **4**: 1-14 [DOI: 10.15226/2374-6904/4/2/00156]

18 **Cassaro CV**, Justulin LA Jr, de Lima PR, Golim MA, Biscola NP, de Castro MV, de Oliveira ALR, Doiche DP, Pereira EJ, Ferreira RS Jr, Barraviera B. Fibrin biopolymer as scaffold candidate to treat bone defects in rats. *J Venom Anim Toxins Incl Trop Dis* 2019; **25**: e20190027 [PMID: 31723344 DOI: 10.1590/1678-9199-JVATITD-2019-0027]

19 **Chen J**, Jiang H. A Comprehensive Review of Concentrated Growth Factors and Their Novel Applications in Facial Reconstructive and Regenerative Medicine. *Aesthetic Plast Surg* 2020; **44**: 1047-1057 [PMID: 31970453 DOI: 10.1007/s00266-020-01620-6]

20 **Lana JFSD**, Purita J, Paulus C, Huber SC, Rodrigues BL, Rodrigues AA, Santana MH, Madureira JL Jr, Malheiros Luzo ÂC, Belangero WD, Annichino-Bizzacchi JM. Contributions for classification of platelet rich plasma - proposal of a new classification: MARSPILL. *Regen Med* 2017; **12**: 565-574 [PMID: 28758836 DOI: 10.2217/rme-2017-0042]

21 **Dohan DM**, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006; **101**: e37-e44 [PMID: 16504849 DOI: 10.1016/j.tripleo.2005.07.008]

22 **Dohan Ehrenfest DM**, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. *Muscles Ligaments Tendons J* 2014; **4**: 3-9 [PMID: 24932440]

23 **Riboh JC**, Saltzman BM, Yanke AB, Fortier L, Cole BJ. Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis. *Am J Sports Med* 2016; **44**: 792-800 [PMID: 25925602 DOI: 10.1177/0363546515580787]

24 **Mariani E**, Canella V, Cattini L, Kon E, Marcacci M, Di Matteo B, Pulsatelli L, Filardo G. Leukocyte-Rich Platelet-Rich Plasma Injections Do Not Up-Modulate Intra-Articular Pro-Inflammatory Cytokines in the Osteoarthritic Knee. *PLoS One* 2016; **11**: e0156137 [PMID: 27258008 DOI: 10.1371/journal.pone.0156137]

25 **Perut F**, Filardo G, Mariani E, Cenacchi A, Pratelli L, Devescovi V, Kon E, Marcacci M, Facchini A, Baldini N, Granchi D. Preparation method and growth factor content of platelet concentrate influence the osteogenic differentiation of bone marrow stromal cells. *Cytotherapy* 2013; **15**: 830-839 [PMID: 23731763 DOI: 10.1016/j.jcyt.2013.01.220]

26 **Rossi LA**, Molina Rómoli AR, Bertona Altieri BA, Burgos Flor JA, Scordo WE, Elizondo CM. Does platelet-rich plasma decrease time to return to sports in acute muscle tear? A randomized controlled trial. *Knee Surg Sports Traumatol Arthrosc* 2017; **25**: 3319-3325 [PMID: 27085364 DOI: 10.1007/s00167-016-4129-7]

27 **Muchedzi TA**, Roberts SB. A systematic review of the effects of platelet rich plasma on outcomes for patients with knee osteoarthritis and following total knee arthroplasty. *Surgeon* 2018; **16**: 250-258 [PMID: 28943099 DOI: 10.1016/j.surge.2017.08.004]

28 **Peerbooms JC**, Lodder P, den Oudsten BL, Doorgeest K, Schuller HM, Gosens T. Positive Effect of Platelet-Rich Plasma on Pain in Plantar Fasciitis: A Double-Blind Multicenter Randomized Controlled Trial. *Am J Sports Med* 2019; **47**: 3238-3246 [PMID: 31603721 DOI: 10.1177/0363546519877181]

29 **Hurley ET**, Lim Fat D, Moran CJ, Mullett H. The Efficacy of Platelet-Rich Plasma and Platelet-Rich Fibrin in Arthroscopic Rotator Cuff Repair: A Meta-analysis of Randomized Controlled Trials. *Am J Sports Med* 2019; **47**: 753-761 [PMID: 29466688 DOI: 10.1177/0363546517751397]

30 **Davey MS**, Hurley ET, Withers D, Moran R, Moran CJ. Anterior Cruciate Ligament Reconstruction with Platelet-Rich Plasma: A Systematic Review of Randomized Control Trials. *Arthroscopy* 2020; **36**: 1204-1210 [PMID: 31987693 DOI: 10.1016/j.arthro.2019.11.004]

31 **Raeissadat SA**, Rayegani SM, Hassanabadi H, Fathi M, Ghorbani E, Babaee M, Azma K. Knee Osteoarthritis Injection Choices: Platelet- Rich Plasma (PRP) Versus Hyaluronic Acid (A one-year randomized clinical trial). *Clin Med Insights Arthritis Musculoskelet Disord* 2015; **8**: 1-8 [PMID: 25624776 DOI: 10.4137/CMAMD.S17894]

32 **Filardo G**, Kon E, Di Martino A, Di Matteo B, Merli ML, Cenacchi A, Fornasari PM, Marcacci M. Platelet-rich plasma *vs* hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. *BMC Musculoskelet Disord* 2012; **13**: 229 [PMID: 23176112 DOI: 10.1186/1471-2474-13-229]

33 **Wu Q**, Luo X, Xiong Y, Liu G, Wang J, Chen X, Mi B. Platelet-rich plasma *vs* hyaluronic acid in knee osteoarthritis: A meta-analysis with the consistent ratio of injection. *J Orthop Surg (Hong Kong)* 2020; **28**: 2309499019887660 [PMID: 31895000 DOI: 10.1177/2309499019887660]

34 **Chahla J**, Cinque ME, Piuzzi NS, Mannava S, Geeslin AG, Murray IR, Dornan GJ, Muschler GF, LaPrade RF. A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. *J Bone Joint Surg Am* 2017; **99**: 1769-1779 [PMID: 29040132 DOI: 10.2106/JBJS.16.01374]

35 **Lana JF**, Weglein A, Sampson SE, Vicente EF, Huber SC, Souza CV, Ambach MA, Vincent H, Urban-Paffaro A, Onodera CM, Annichino-Bizzacchi JM, Santana MH, Belangero WD. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. *J Stem Cells Regen Med* 2016; **12**: 69-78 [PMID: 28096631 DOI: 10.46582/jsrm.1202011]

36 **Martins Shimojo AA**, Santos Duarte ADS, Santos Duarte Lana JF, Malheiros Luzo ÂC, Fernandes AR, Sanchez-Lopez E, Barbosa Souto E, Andrade Santana MH. Association of Platelet-Rich Plasma and Auto-Crosslinked Hyaluronic Acid Microparticles: Approach for Orthopedic Application. *Polymers (Basel)* 2019; **11** [PMID: 31561615 DOI: 10.3390/polym11101568]

37 **Dominici M**, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; **8**: 315-317 [PMID: 16923606 DOI: 10.1080/14653240600855905]

38 **Holton J**, Imam M, Ward J, Snow M. The Basic Science of Bone Marrow Aspirate Concentrate in Chondral Injuries. *Orthop Rev (Pavia)* 2016; **8**: 6659 [PMID: 27761221 DOI: 10.4081/or.2016.6659]

39 **Chamberlain G**, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells* 2007; **25**: 2739-2749 [PMID: 17656645 DOI: 10.1634/stemcells.2007-0197]

40 **Yoshimura K**, Shigeura T, Matsumoto D, Sato T, Takaki Y, Aiba-Kojima E, Sato K, Inoue K, Nagase T, Koshima I, Gonda K. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. *J Cell Physiol* 2006; **208**: 64-76 [PMID: 16557516 DOI: 10.1002/jcp.20636]

41 **Jackson WM**, Nesti LJ, Tuan RS. Concise review: clinical translation of wound healing therapies based on mesenchymal stem cells. *Stem Cells Transl Med* 2012; **1**: 44-50 [PMID: 23197639 DOI: 10.5966/sctm.2011-0024]

42 **Caplan AI**. Mesenchymal Stem Cells: Time to Change the Name! *Stem Cells Transl Med* 2017; **6**: 1445-1451 [PMID: 28452204 DOI: 10.1002/sctm.17-0051]

43 **Barry F**, Murphy M. Mesenchymal stem cells in joint disease and repair. *Nat Rev Rheumatol* 2013; **9**: 584-594 [PMID: 23881068 DOI: 10.1038/nrrheum.2013.109]

44 **Lopa S**, Colombini A, Moretti M, de Girolamo L. Injective mesenchymal stem cell-based treatments for knee osteoarthritis: from mechanisms of action to current clinical evidences. *Knee Surg Sports Traumatol Arthrosc* 2019; **27**: 2003-2020 [PMID: 30159741 DOI: 10.1007/s00167-018-5118-9]

45 **Sawai CM**, Babovic S, Upadhaya S, Knapp DJHF, Lavin Y, Lau CM, Goloborodko A, Feng J, Fujisaki J, Ding L, Mirny LA, Merad M, Eaves CJ, Reizis B. Hematopoietic Stem Cells Are the Major Source of Multilineage Hematopoiesis in Adult Animals. *Immunity* 2016; **45**: 597-609 [PMID: 27590115 DOI: 10.1016/j.immuni.2016.08.007]

46 **Bornes TD**, Adesida AB, Jomha NM. Articular Cartilage Repair with Mesenchymal Stem Cells After Chondrogenic Priming: A Pilot Study. *Tissue Eng Part A* 2018; **24**: 761-774 [PMID: 28982297 DOI: 10.1089/ten.TEA.2017.0235]

47 **Bianco P**. Bone and the hematopoietic niche: a tale of two stem cells. *Blood* 2011; **117**: 5281-5288 [PMID: 21406722 DOI: 10.1182/blood-2011-01-315069]

48 **Chahla J**, Dean CS, Moatshe G, Pascual-Garrido C, Serra Cruz R, LaPrade RF. Concentrated Bone Marrow Aspirate for the Treatment of Chondral Injuries and Osteoarthritis of the Knee: A Systematic Review of Outcomes. *Orthop J Sports Med* 2016; **4**: 2325967115625481 [PMID: 26798765 DOI: 10.1177/2325967115625481]

49 **Lv FJ**, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. *Stem Cells* 2014; **32**: 1408-1419 [PMID: 24578244 DOI: 10.1002/stem.1681]

50 **Hernigou P**, Desroches A, Queinnec S, Flouzat Lachaniette CH, Poignard A, Allain J, Chevallier N, Rouard H. Morbidity of graft harvesting *vs* bone marrow aspiration in cell regenerative therapy. *Int Orthop* 2014; **38**: 1855-1860 [PMID: 24658874 DOI: 10.1007/s00264-014-2318-x]

51 **Schottel PC**, Warner SJ. Role of Bone Marrow Aspirate in Orthopedic Trauma. *Orthop Clin North Am* 2017; **48**: 311-321 [PMID: 28577780 DOI: 10.1016/j.ocl.2017.03.005]

52 **Hernigou J**, Alves A, Homma Y, Guissou I, Hernigou P. Anatomy of the ilium for bone marrow aspiration: map of sectors and implication for safe trocar placement. *Int Orthop* 2014; **38**: 2585-2590 [PMID: 24781923 DOI: 10.1007/s00264-014-2353-7]

53 **Hernigou P**, Homma Y, Flouzat Lachaniette CH, Poignard A, Allain J, Chevallier N, Rouard H. Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells. *Int Orthop* 2013; **37**: 2279-2287 [PMID: 23881064 DOI: 10.1007/s00264-013-2017-z]

54 **Gaul F**, Bugbee WD, Hoenecke HR Jr, D'Lima DD. A Review of Commercially Available Point-of-Care Devices to Concentrate Bone Marrow for the Treatment of Osteoarthritis and Focal Cartilage Lesions. *Cartilage* 2019; **10**: 387-394 [PMID: 29652173 DOI: 10.1177/1947603518768080]

55 **Burnham T**, Conger A, Tate Q, Cushman DM, Kendall R, Schneider B, McCormick ZL. The Effectiveness and Safety of Percutaneous Platelet-Rich Plasma and Bone Marrow Aspirate Concentrate for the Treatment of Suspected Discogenic Low Back Pain: a Comprehensive Review. *Curr Phys Med Rehabil Rep* 2019; **7**: 372-384 [DOI: 10.1007/s40141-019-00243-6]

56 **Dhillon MS**, Karna SK, Dhatt SS, Behera P, Bhatia A. Can Platelet rich plasma stimulate human ACL growth in culture? A preliminary experience. *Muscles Ligaments Tendons J* 2015; **5**: 156-161 [PMID: 26605188 DOI: 10.11138/mLtj/2015.5.3.156]

57 **Yuan T**, Zhang CQ, Wang JH. Augmenting tendon and ligament repair with platelet-rich plasma (PRP). *Muscles Ligaments Tendons J* 2013; **3**: 139-149 [PMID: 24367773]

58 **Rubio-Azpeitia E**, Andia I. Partnership between platelet-rich plasma and mesenchymal stem cells: *in vitro* experience. *Muscles Ligaments Tendons J* 2014; **4**: 52-62 [PMID: 24932448]

59 **Warnke PH**, Humpe A, Strunk D, Stephens S, Warnke F, Wiltfang J, Schallmoser K, Alamein M, Bourke R, Heiner P, Liu Q. A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies. *J Craniomaxillofac Surg* 2013; **41**: 153-161 [PMID: 22878221 DOI: 10.1016/j.jcms.2012.07.003]

60 **Mishra A**, Tummala P, King A, Lee B, Kraus M, Tse V, Jacobs CR. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. *Tissue Eng Part C Methods* 2009; **15**: 431-435 [PMID: 19216642 DOI: 10.1089/ten.tec.2008.0534]

61 **Krüger JP**, Hondke S, Endres M, Pruss A, Siclari A, Kaps C. Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells. *J Orthop Res* 2012; **30**: 845-852 [PMID: 22058056 DOI: 10.1002/jor.22005]

62 **Zhong W**, Sumita Y, Ohba S, Kawasaki T, Nagai K, Ma G, Asahina I. In vivo comparison of the bone regeneration capability of human bone marrow concentrates vs. platelet-rich plasma. *PLoS One* 2012; **7**: e40833 [PMID: 22808272 DOI: 10.1371/journal.pone.0040833]

63 **Wojtowicz A**, Chaberek S, Urbanowska E, Ostrowski K. Comparison of efficiency of platelet rich plasma, hematopoieic stem cells and bone marrow in augmentation of mandibular bone defects. *N Y State Dent J* 2007; **73**: 41-45 [PMID: 17472185]

64 **Kretlow JD**, Spicer PP, Jansen JA, Vacanti CA, Kasper FK, Mikos AG. Uncultured marrow mononuclear cells delivered within fibrin glue hydrogels to porous scaffolds enhance bone regeneration within critical-sized rat cranial defects. *Tissue Eng Part A* 2010; **16**: 3555-3568 [PMID: 20715884 DOI: 10.1089/ten.TEA.2010.0471]

65 **Lee DH**, Ryu KJ, Kim JW, Kang KC, Choi YR. Bone marrow aspirate concentrate and platelet-rich plasma enhanced bone healing in distraction osteogenesis of the tibia. *Clin Orthop Relat Res* 2014; **472**: 3789-3797 [PMID: 24599650 DOI: 10.1007/s11999-014-3548-3]

66 **Centeno C**, Markle J, Dodson E, Stemper I, Williams C, Hyzy M, Ichim T, Freeman M. Symptomatic anterior cruciate ligament tears treated with percutaneous injection of autologous bone marrow concentrate and platelet products: a non-controlled registry study. *J Transl Med* 2018; **16**: 246 [PMID: 30176875 DOI: 10.1186/s12967-018-1623-3]

67 **Hede K**, Christensen BB, Jensen J, Foldager CB, Lind M. Combined Bone Marrow Aspirate and Platelet-Rich Plasma for Cartilage Repair: Two-Year Clinical Results. *Cartilage* 2019: 1947603519876329 [PMID: 31538811 DOI: 10.1177/1947603519876329]

68 **Campbell KJ**, Boykin RE, Wijdicks CA, Erik Giphart J, LaPrade RF, Philippon MJ. Treatment of a hip capsular injury in a professional soccer player with platelet-rich plasma and bone marrow aspirate concentrate therapy. *Knee Surg Sports Traumatol Arthrosc* 2013; **21**: 1684-1688 [PMID: 23052123 DOI: 10.1007/s00167-012-2232-y]

69 **Wang X**, Qiu Y, Triffitt J, Carr A, Xia Z, Sabokbar A. Proliferation and differentiation of human tenocytes in response to platelet rich plasma: an *in vitro* and *in vivo* study. *J Orthop Res* 2012; **30**: 982-990 [PMID: 22102328 DOI: 10.1002/jor.22016]

70 **Martin JR**, Houdek MT, Sierra RJ. Use of concentrated bone marrow aspirate and platelet rich plasma during minimally invasive decompression of the femoral head in the treatment of osteonecrosis. *Croat Med J* 2013; **54**: 219-224 [PMID: 23771751 DOI: 10.3325/cmj.2013.54.219]

71 **Centeno C**, Fausel Z, Stemper I, Azuike U, Dodson E. A Randomized Controlled Trial of the Treatment of Rotator Cuff Tears with Bone Marrow Concentrate and Platelet Products Compared to Exercise Therapy: A Midterm Analysis. *Stem Cells Int* 2020; **2020**: 5962354 [PMID: 32399045 DOI: 10.1155/2020/5962354]

72 **Kim SJ**, Kim EK, Kim SJ, Song DH. Effects of bone marrow aspirate concentrate and platelet-rich plasma on patients with partial tear of the rotator cuff tendon. *J Orthop Surg Res* 2018; **13**: 1 [PMID: 29298726 DOI: 10.1186/s13018-017-0693-x]

73 **Cassano JM**, Kennedy JG, Ross KA, Fraser EJ, Goodale MB, Fortier LA. Bone marrow concentrate and platelet-rich plasma differ in cell distribution and interleukin 1 receptor antagonist protein concentration. *Knee Surg Sports Traumatol Arthrosc* 2018; **26**: 333-342 [PMID: 26831858 DOI: 10.1007/s00167-016-3981-9]

74 **Sugaya H**, Yoshioka T, Kato T, Taniguchi Y, Kumagai H, Hyodo K, Ohneda O, Yamazaki M, Mishima H. Comparative Analysis of Cellular and Growth Factor Composition in Bone Marrow Aspirate Concentrate and Platelet-Rich Plasma. *Bone Marrow Res* 2018; **2018**: 1549826 [PMID: 29682351 DOI: 10.1155/2018/1549826]

75 **Ziegler CG**, Van Sloun R, Gonzalez S, Whitney KE, DePhillipo NN, Kennedy MI, Dornan GJ, Evans TA, Huard J, LaPrade RF. Characterization of Growth Factors, Cytokines, and Chemokines in Bone Marrow Concentrate and Platelet-Rich Plasma: A Prospective Analysis. *Am J Sports Med* 2019; **47**: 2174-2187 [PMID: 31034242 DOI: 10.1177/0363546519832003]

76 **Andia I**, Sánchez M, Maffulli N. Basic Science: Molecular and Biological Aspects of Platelet-Rich Plasma Therapies. *Oper Tech Orthop* 2012; **22**: 3-9 [DOI: 10.1053/j.oto.2011.09.005]

77 **Bastian OW**. The two faces of inflammation during fracture healing. 2018

78 **Perez AG**, Lana JF, Rodrigues AA, Luzo AC, Belangero WD, Santana MH. Relevant aspects of centrifugation step in the preparation of platelet-rich plasma. *ISRN Hematol* 2014; **2014**: 176060 [PMID: 25006472 DOI: 10.1155/2014/176060]

79 **de Melo BAG**, Martins Shimojo AA, Marcelino Perez AG, Duarte Lana JFS, Andrade Santana MH. Distribution, recovery and concentration of platelets and leukocytes in L-PRP prepared by centrifugation. *Colloids Surf B Biointerfaces* 2018; **161**: 288-295 [PMID: 29096373 DOI: 10.1016/j.colsurfb.2017.10.046]

80 **Melo BAG**, Luzo ÂCM, Lana JFSD, Santana MHA. Centrifugation Conditions in the L-PRP Preparation Affect Soluble Factors Release and Mesenchymal Stem Cell Proliferation in Fibrin Nanofibers. *Molecules* 2019; **24** [PMID: 31357568 DOI: 10.3390/molecules24152729]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** September 26, 2020

**First decision:** November 3, 2020

**Article in press:**

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cao T,Sorio C, Zhang YG **S-Editor:** Gao CC **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**

****

**Figure 1 Cell and platelet interactions in platelet-rich plasma-bone marrow aspirate concentrate milieu.** Monocytes contained in bone marrow aspirate concentrate are further stimulated in the presence of platelet-rich plasma. Macrophage (MΦ) 1 is characterized by inflammatory cytokine secretion (interferon-γ) and nitric oxide production, resulting in an effective pathogen killing mechanism. The MΦ1 phenotype also produces vascular endothelial growth factor and fibroblast growth factor. The MΦ2 phenotype consists of anti-inflammatory cells with a high phagocytosis capacity. MΦ2 produces extracellular matrix components, angiogenic and chemotactic factors, and interleukin-10. In addition to pathogen defense, MΦ2 can alleviate the inflammatory response and promote tissue repair. Orange: monocyte; Dark purple: neutrophil; Light blue: macrophage; Dark blue: mesenchymal stem cells; Light purple: activated platelets; Green: growth factors; Dark yellow: fibrin fibers.

**Table 1 Relevant article conclusions (preclinical and clinical) in the pertinent literature on the use of bone marrow aspirate concentrate-platelet-rich plasma products and the comparison between both products**

|  |  |
| --- | --- |
| **Ref.** | **Conclusions** |
| Moatshe *et al*[3] (2017) | Strong data supporting the optimal preparation methods and composition for widely used biologic agents, such as PRP and BMAC, largely remain absent from the literature |
| Yamaguchi *et al*[8] (2019) | Different formulations of biomaterials have been used as carriers for PRP and BMAC in order to increase regenerative processes. The most common biomaterials utilized in conjunction with PRP and BMAC clinical trials are organic scaffolds and natural or synthetic polymers |
| Burnham *et al*[55] (2019) | Evidence for use of percutaneous, fluoroscopy-guided, intradiscal PRP or BMAC for the treatment of suspected discogenic low back pain appears safe, potentially positive but is limited due to low-quality studies, natural history of discogenic pain, and variable reporting characteristics |
| Rubio-Azpeitia *et al*[58] (2014) | Overall PRP stimulates MSC proliferation, preserves MSCs multipotency and does not interfere with any lineage differentiation. PRP (as platelet lysate or releasate) preserves the immune-privileged potential of MSCs and may delay the appearance of the senescent phenotype |
| Mishra *et al*[60] (2009) | Results confirm that PRP enhances MSC proliferation and suggest that PRP causes chondrogenic differentiation of MSC *in vitro* |
| Krüger *et al*[61] (2013) | Results suggest that human PRP may enhance the migration and stimulate the chondrogenic differentiation of human subchondral progenitor cells known from microfracture |
| Zhong *et al*[62] (2012) | Both human BMACs and PRP may provide therapeutic benefits in bone tissue engineering applications. These fractions possess a similar ability to enhance early-phase bone regeneration |
| Wojtowicz *et al*[63] (2007) | Newly formed bone augmented under the influence of PRP shows the closest similarity to the control contralateral bone in comparison to BM-MSCs |
| Lee *et al*[65] (2014) | Autologous BMAC combined with PRP injection at the osteotomy site helped improve bone healing in distraction osteogenesis of the tibia, although the effect size was small |
| Centeno *et al*[66] (2018) | ACL treatment with percutaneous injection of BMC and platelet products shows promise as a nonsurgical alternative. However, a larger randomized controlled trial is warranted to confirm these findings |
| Hede *et al*[67] (2019) | Treatment of cartilage injuries using combined BMAC and PRP improved subjective clinical outcome scores and pain scores at 1 and 2 yr postoperatively. MRI and histology indicated repair tissue inferior to the native hyaline cartilage |
| Campbell *et al*[68] (2013) | A series of orthobiologic treatments with PRP and BMAC improved the patient’s pain and strength as well as the morphologic appearance of the hip capsule and gluteus minimus tendon on MRI |
| Martin *et al*[70] (2013) | The use of a minimally invasive femoral head decompression augmented with concentrated bone marrow and PRP resulted in significant pain relief and halted the progression of disease in a majority of patients |
| Centeno *et al*[71] (2020) | Findings suggest that ultrasound-guided BMC and platelet product injections are a safe and useful alternative to conservative exercise therapy of torn, nonretracted supraspinatus tendons |
| Kim *et al*[72] (2018) | BMAC-PRP improved pain and shoulder function in patients with partial tear of the rotator cuff tendon |
| Cassano *et al*[73] (2018) | Colony-forming units were increased in both BMAC compared to BMA (*P* < 0.0001). Platelet counts were not significantly different between BMAC and PRP. TGF-β1 and PDGF were not different between BMAC and PRP. IL-1ra concentrations were greater (*P* = 0.0018) in BMAC samples than in PRP. The IL-1ra/IL-1β ratio in all BMAC samples was above the value reported to inhibit IL-1β |
| Sugaya *et al*[74] (2018) | The concentration of b-FGF was higher in BMAC than in PRP (𝑃 < 0.001), whereas no significant differences in the levels of PDGF-BB, VEGF, TGF-𝛽1, and BMP-2 were observed between the two types of samples. BMAC had an average of 1.90% CD34+ and 0.03% CD31-45-90+105+ cells (no cells in PRP) and higher levels of b-FGF than those of PRP |
| Ziegler *et al*[75] (2019) | BMAC is a clinically relevant source of anti-inflammatory biologic therapy that may be more effective in treating osteoarthritis and for use as an intra-articular biologic source for augmented healing in the postsurgical inflammatory and healing phases, owing to its significantly higher concentration of IL-1Ra as compared with Lr-PRP and Lp-PRP. Additionally, Lr-PRP had a significantly higher concentration of IL-1Ra than Lp-PRP. In cases where increased vascularity and healing are desired for pathological or injured tissues, including muscle and tendon, Lr-PRP may be optimal given its higher overall concentrations of PDGF, TGF-β, EGF, VEGF, and soluble CD40 ligand |

BMAC: Bone marrow aspirate concentrate; PRP: Platelet-rich plasma; MSC: Mesenchymal stem cell; BM-MSCs: Bone marrow mesenchymal stem cells; ACL: Anterior cruciate ligament; BMC: Bone marrow concentrate; MRI: Magnetic resonance imaging; BMA: Bone marrow aspirate; TGF-β: Transforming growth factor β; PDGF: Platelet-derived growth factor; IL: Interleukin; b-FGF: Basic fibroblast growth factor; VEGF: Vascular endothelial growth factor; BMP-2: Bone morphogenetic protein-2; Lr-PRP: Leukocyte-platelet-rich plasma; Lp-PRP: Leukocyte-poor platelet-rich plasma; EGF: Epidermal growth factor.